17 / 36
AEs que condicionaron
suspensión del tratamiento
17
• Pyrexia/chills was the most common AE leading to treatment discontinuation (12.4% of patients)
AEs, n (%)
Dabrafenib + Trametinib
n = 435
Placebo
n = 432
Any AE leading to discontinuation
114 (26)
12 (3)
Pyrexia
38 (9)
0
Chills
16 (4)
0
Fatigue
8 (2)
0
ALT increase
7 (2)
0
Headache
6 (1)
0
Arthralgia
5 (1)
0
AST increase
5 (1)
0
Nausea
5 (1)
1 (< 1)
Neutropenia
5 (1)
0
AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase.
Atkinson V, et al. ESMO 2018